SMA Peg denied as duplicate or overlapping therapy by Anthem?

Anthem's specific coverage criteria for sma peg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Anthem Denied This Claim — and Why It's Appealable

A duplicate-therapy denial for pegylated therapy in spinal muscular atrophy (SMA) — commonly referring to a disease-modifying treatment in the emerging SMA pipeline — means Anthem has identified another active treatment for the same condition on the patient's medication profile and concluded both cannot be covered simultaneously. In SMA, where treatment options differ substantially in mechanism, route of administration, and patient profile, a duplicate-therapy classification is frequently incorrect and is one of the more straightforwardly appealable denial types when the clinical record is clearly documented.

## Your Federal Appeal Rights

Under ACA §2719, you are entitled to a full internal appeal and then an independent external review through an IRO outside Anthem's control. For employer-sponsored plans subject to ERISA §503, you have the right to a full and fair review. The external review window is generally four months from the denial date. If the denied therapy addresses an urgent or deteriorating aspect of the patient's condition, request expedited review.

## Concrete Appeal Steps

1. Obtain the denial letter identifying which existing therapy Anthem considers duplicative and the policy provision applied. 2. Request Anthem's medical/coverage policy for SMA treatments and for duplicate-therapy determinations. 3. File a Level 1 internal appeal demonstrating that the two therapies are clinically distinct — different mechanisms, indications, or patient subgroup — and that simultaneous use is consistent with the FDA-approved labeling and applicable professional guidelines. 4. Escalate to external review if Level 1 is upheld; IRO reviewers with neuromuscular expertise regularly distinguish between therapies in complex diseases.

## Documentation to Gather

• Diagnosis confirmation: Genetic testing confirming SMA type and relevant molecular characteristics relevant to treatment selection.
• Current treatment record: Complete medication list with dates initiated, doses (from physician records, not this document), and clinical response for each active therapy.
• Prescriber differentiation letter: A letter from the treating neurologist explaining in specific clinical terms how the requested therapy is mechanistically and clinically distinct from any existing therapy, why both are simultaneously appropriate, and referencing the FDA-approved labeling for each agent and the applicable guideline organization (e.g., the SMA Foundation clinical guidelines or relevant AAN guidance).
• Clinical severity and trajectory: Notes documenting current functional status, disease progression markers, and why the existing therapy alone is insufficient.

## Criteria-Mapping Structure

Create a table listing each element of Anthem's duplicate-therapy criteria on the left; on the right, provide the specific chart or labeling fact that shows the requested therapy is not duplicative. Where Anthem's policy references FDA-approved indications, attach the relevant section of each drug's prescribing information to let the label speak for itself.